# Allotera Therapeutics

> Clinical-stage allogeneic (off-the-shelf) CAR-T company for T-cell malignancies — formerly Wugen.

## Why it is interesting

St. Louis clinical biotech (formerly Wugen) advancing off-the-shelf CD7 CAR-T; closed $115M financing (Aug 2025) led by Fidelity to fund the pivotal T-RRex study — WashU-rooted allogeneic cell therapy bet.

## Profile

- **Latest funding:** Equity financing (Series C–class) — $115M (August 2025)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $115M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-26
- **Latest funding investors:** Fidelity Management & Research Company, RiverVest Venture Partners, Lightchain Capital, Abingworth, Tybourne Capital Management

## Key facts

- Equity financing (Aug 2025): $115M led by Fidelity to advance pivotal T-RRex study (company / BioPharma Dive)
- Formerly Wugen; rebranded to Allotera Therapeutics (alloteratx.com)
- Lead asset: soficabtagene geleucel (WU-CART-007), allogeneic CD7 CAR-T
- Prior Series B (2021): $172M led by Tybourne/Abingworth per coverage

## Funding history

- Equity financing (Series C–class) · $115M · August 2025
  Source: https://wugen.com/wugen-secures-115-million-to-advance-pivotal-study-of-first-in-class-allogeneic-car-t-therapy-wu-cart-007/

## Related articles

- https://venturecapitaltracker.com/st-louis-startups-and-vc-firms-2026

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** July 26, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/allotera-therapeutics